Aripiprazole approved for autism-related irritability.
Risperidone (Risperdal), also an atypical antipsychotic, was approved in 2006 for the same indication for children aged 5-16 years.
Aripiprazole, marketed as Abilify by the manufacturers, Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co., was initially approved by the FDA in 2002 for schizophrenia. Aripiprazole has been approved for several other adult and pediatric indications, including treatment of schizophrenia in adolescents aged 13-17 years, and bipolar disorder indications down to age 10 years. The recommended dose for the new indication is 5-10 mg day (starting at 2 mg per day, with the maximum dose of 15 mg per day).
The effectiveness of aripiprazole for the autistic disorder indication was established in two 8-week multicenter studies of children and adolescents aged 6-17 years (more than 75% were younger than age 13 years), according to the revised label. They met the DSM-IV criteria for autistic disorder and exhibited behaviors that included tantrums, aggression, and/or self-injurious behavior.
In one study of 98 children and adolescents, those on aripiprazole (at a starting dose of 2 mg/day increasing up to 15 mg per day based on clinical response), had significantly improved scores when compared to those on placebo at 8 weeks on two scales: the irritability subscale of the Aberrant Behavior Checklist (ABC-I), a caregiver-rated assessment tool, and the Clinical Global Impression-Improvement (CGI-I) scale, a tool used to monitor treatment outcomes in psychiatric disorders.
In the second study of 218 children and adolescents, those on a fixed dose of aripiprazole (5 mg, 10 mg, or 15 mg per day) had significantly improved scores on the ABC-I Subscale, compared with those on placebo.
In a pooled analysis of the two studies, mean weight gain among those on aripiprazole was 1.6 kg, compared with 0.4 kg among those on placebo. During the study, 26% of those on aripiprazole and 7% of those on placebo experienced clinically significant weight gain, defined as at least a 7% change from baseline, according to the company statement.
Other common adverse events that were more common among treated patients included sedation, affecting 21% of those on aripiprazole compared with 4% of those on placebo, fatigue (17% vs. 2%), vomiting (14% vs. 7%), somnolence (10% vs. 4%), tremor (10% vs. 0%), drooling (9% vs. 0%), and extrapyramidal disorder (6% vs. 0%).
These studies were "not designed or intended to evaluate" aripiprazole for treatment of the core symptoms of autistic disorder, the company statement said.
|Printer friendly Cite/link Email Feedback|
|Publication:||Clinical Psychiatry News|
|Date:||Dec 1, 2009|
|Previous Article:||New data point to extent of trauma at Virginia Tech: more than 15% of students had PTSD.|
|Next Article:||Health quality measures have plateaued, report finds.|